ArticleBone marrow transplantation2008
Impact of early relapse after auto-SCT for multiple myeloma.
Article in Bone marrow transplantation, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 103 citations in OpenAlex.
- Challenging the concept of functional high-risk myeloma through transcriptional and genetic profiling.Blood · 2025Trial
- Isatuximab plus carfilzomib and dexamethasone in patients with earlyHaematologica · 2024Trial
- Early relapse after single auto-SCT for multiple myeloma is a major predictor of survival in the era of novel agents.Bone marrow transplantation · 2015Trial
- Quantification of clonal circulating plasma cells in relapsed multiple myeloma.British journal of haematology · 2014Trial
- Second auto-SCT for treatment of relapsed multiple myeloma.Bone marrow transplantation · 2013Trial
- The Strange Case of Functional High-Risk Multiple Myeloma Patients: Is It Possible to Identify Them in Clinical Practice?Cancers · 2025Article
- Impact of residual clonal plasma cells in S-phase at the time of autologous stem cell transplantation on clinical outcomes.Blood cancer journal · 2025Article
- Efficacy and Safety of Isatuximab, Carfilzomib, and Dexamethasone (IsaKd) in Multiple Myeloma Patients at the First Relapse After Autologous Stem Cell Transplantation and Lenalidomide Maintenance: Results from the Multicenter, Real-Life AENEID Study.Pharmaceuticals (Basel, Switzerland) · 2025Article
- High-risk features of early relapse in newly-diagnosed multiple myeloma: The impact of cytogenetics and response to initial therapy.HemaSphere · 2025Article
- Consensus Guidelines and Recommendations for the anti-CD38-based Therapy in Clinical Practice for Relapsed/Refractory Multiple Myeloma: From the Pan-Pacific Multiple Myeloma Working Group.Clinical hematology international · 2025Review
- Article
- Cardiac Interventions in Patients With Active, Advanced Solid and Hematologic Malignancies:JACC. CardioOncology · 2023Review
- ML-based sequential analysis to assist selection between VMP and RD for newly diagnosed multiple myeloma.NPJ precision oncology · 2023Article
- Review
- Prognostic nomogram for multiple myeloma early relapse after autologous stem cell transplant in the novel agent era.Cancer medicine · 2023Article
- Definers and drivers of functional high-risk multiple myeloma: insights from genomic, transcriptomic, and immune profiling.Frontiers in oncology · 2023Review
- Perturbation of the gut microbiome and association with outcomes following autologous stem cell transplantation in patients with multiple myeloma.Leukemia & lymphoma · 2023Article
- High serum miR-223-3p expression level predicts complete response and prolonged overall survival in multiple myeloma patients undergoing autologous hematopoietic stem cell transplantation.Frontiers in oncology · 2023Article
- Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee.Blood cancer journal · 2022Review
- High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions.Blood cancer journal · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Auto-SCT is an effective therapy for patients with multiple myeloma (MM), but nearly a fifth of these patients relapse within a year of auto-SCT. We studied 494 patients, undergoing auto-SCT within 12 months of diagnosis of MM. Patients were divided into two groups: early relapse (relapse <or=12 months from auto-SCT) and late relapse (either relapsed >12 months after auto-SCT or disease free at the last follow up). One hundred twenty patients (24%) were in the early relapse and 374 (76%) were in the late-relapse groups. The early relapse group had a significantly shorter median overall survival (OS) from diagnosis (26.6 vs 90.7 months; P<0.001) and from auto-SCT (20.1 vs 82.5 months; P<0.001). Among the 345 patients who have relapsed after auto-SCT, median OS from relapse was 10.8 months in the early relapse group compared to 41.8 months for the rest (P<0.001) and was longer with increasing duration of response to the SCT. In multivariate analyses, labeling index >or=1% at transplant, greater than one treatment regimen prior to auto-SCT, and failure to achieve a complete response were predictive of early relapse. Patients who relapse within 12 months of an auto-SCT have a poor outcome and should be offered trials evaluating novel treatment approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.